NeuroSense Therapeutics Ltd. – NASDAQ:NRSN
NeuroSense Therapeutics Ltd. stock price today
$1.17
-0.11
-8.59%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
NeuroSense Therapeutics Ltd. stock price monthly change
+26.73%
month
NeuroSense Therapeutics Ltd. stock price quarterly change
+26.73%
quarter
NeuroSense Therapeutics Ltd. stock price yearly change
+71.81%
year
NeuroSense Therapeutics Ltd. key metrics
Market Cap | 25.20M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -0.86 |
Revenue | N/A |
EBITDA | -10.68M |
Income | -12.79M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeNeuroSense Therapeutics Ltd. stock price history
NeuroSense Therapeutics Ltd. stock forecast
NeuroSense Therapeutics Ltd. financial statements
| Jun 2023 | 0 | -5.22M | |
|---|---|---|---|
| Sep 2023 | 0 | 784K | |
| Dec 2023 | 0 | -2.95M | |
| Mar 2024 | 0 | -5.40M |
| 2025 | 0 | -15.17M | |
|---|---|---|---|
| 2026 | 11.47M | -8.11M | -70.73% |
| 2027 | 23.07M | 1.50M | 6.5% |
| 2028 | 37.13M | 7.91M | 21.31% |
Analysts Price target
Financials & Ratios estimates
| 2024-03-22 | -0.2 | -0.16 |
|---|---|---|
| 2024-04-05 | -0.2 | -0.16 |
| 2024-08-28 | -0.2 | -0.04747 |
| 2024-12-18 | -0.16 | -0.11 |
| Jun 2023 | 7868000 | 9.41M | 119.64% |
|---|---|---|---|
| Sep 2023 | 5386000 | 5.58M | 103.64% |
| Dec 2023 | 3176000 | 5.05M | 159.01% |
| Mar 2024 | 1446000 | 8.43M | 583.61% |
| Mar 2023 | 0 | 0 | 0 |
|---|---|---|---|
| Jun 2023 | 1.78K | 0 | 0 |
| Sep 2023 | 0 | 0 | 0 |
| Dec 2023 | 0 | 0 | 0 |
NeuroSense Therapeutics Ltd. alternative data
| Aug 2023 | 14 |
|---|---|
| Sep 2023 | 14 |
| Oct 2023 | 14 |
| Nov 2023 | 14 |
| Dec 2023 | 14 |
| Jan 2024 | 14 |
| Feb 2024 | 14 |
| Mar 2024 | 14 |
| Apr 2024 | 14 |
| May 2024 | 18 |
| Jun 2024 | 18 |
| Jul 2024 | 18 |
NeuroSense Therapeutics Ltd. other data
1.10%
+0.79%
of NRSN is owned by hedge funds
123.81K
+89.11K
shares is hold by hedge funds
-
What's the price of NeuroSense Therapeutics Ltd. stock today?
One share of NeuroSense Therapeutics Ltd. stock can currently be purchased for approximately $1.17.
-
When is NeuroSense Therapeutics Ltd.'s next earnings date?
Unfortunately, NeuroSense Therapeutics Ltd.'s (NRSN) next earnings date is currently unknown.
-
Does NeuroSense Therapeutics Ltd. pay dividends?
No, NeuroSense Therapeutics Ltd. does not pay dividends.
-
How much money does NeuroSense Therapeutics Ltd. make?
NeuroSense Therapeutics Ltd. has a market capitalization of 25.20M. NeuroSense Therapeutics Ltd. made a loss 10.11M US dollars in net income (profit) last year or -$0.11 on an earnings per share basis.
-
What is NeuroSense Therapeutics Ltd.'s stock symbol?
NeuroSense Therapeutics Ltd. is traded on the NASDAQ under the ticker symbol "NRSN".
-
What is NeuroSense Therapeutics Ltd.'s primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of NeuroSense Therapeutics Ltd.?
Shares of NeuroSense Therapeutics Ltd. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does NeuroSense Therapeutics Ltd. have?
As Jul 2024, NeuroSense Therapeutics Ltd. employs 18 workers, which is 29% more then previous quarter.
-
When NeuroSense Therapeutics Ltd. went public?
NeuroSense Therapeutics Ltd. is publicly traded company for more then 3 years since IPO on 9 Dec 2021.
-
What is NeuroSense Therapeutics Ltd.'s official website?
The official website for NeuroSense Therapeutics Ltd. is neurosense-tx.com.
-
How can i contact NeuroSense Therapeutics Ltd.?
NeuroSense Therapeutics Ltd. can be reached via phone at +972 9 799 6183.
NeuroSense Therapeutics Ltd. company profile:
NeuroSense Therapeutics Ltd.
neurosense-tx.comExchange:
NASDAQ
Full time employees:
18
Industry:
Biotechnology
Sector:
Healthcare
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
Building B
Herzliya, 4672562
Herzliya, 4672562
CIK: 0001875091
ISIN: IL0011809592
CUSIP: M74240108
